Clonidine [SEP] Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes a

Clonidine [SEP] An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonl


attention-deficit/hyperactivity disorder [SEP] Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.

Attention Deficit Disorder with Hyperactivity [SEP] A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattent


clonidine [SEP] OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-d


methylphenidate [SEP] ine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD

Methylphenidate [SEP] A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLE


attention-deficit/hyperactivity disorder [SEP] f clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: In a 16-week multicenter, double-blind trial, 1


ADHD [SEP] date in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: In a 16-week multicenter, double-blind trial, 122 chi


bradycardia [SEP] diograms and vital signs. RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not trea

Bradycardia [SEP] Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. Th


Drowsiness [SEP] but not associated with higher rates of early study withdrawal. Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks

Disorders of Excessive Somnolence [SEP] Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include pr


Clonidine [SEP] clonidine, but generally resolved by 6 to 8 weeks. CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tole


drowsiness [SEP] cardia and advise patients about the high likelihood of initial drowsiness.


Thalidomide [SEP] Thalidomide has limited single-agent activity in relapsed or refractory ind

Thalidomide [SEP] A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic ef


non-Hodgkin lymphomas [SEP] imited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Lymphoma, Non-Hodgkin [SEP] Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to


Cancer [SEP] ractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


Leukemia [SEP] olent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Leukemia [SEP] A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukoc


Thalidomide [SEP] Thalidomide is an immunomodulatory agent with demonstrated activity in mult


multiple myeloma [SEP] mide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma. Its activ

Multiple Myeloma [SEP] A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia,


mantle cell lymphoma [SEP] odulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma. Its activity is believed to be

Lymphoma, Mantle-Cell [SEP] A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells.


lymphoplasmacytic lymphoma [SEP] nstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma. Its activity is believed to be due modulation of the tumour mi

Lymphoma [SEP] A general term for various neoplastic diseases of the lymphoid tissue.


tumour [SEP]  lymphoma. Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammato


lymphomas [SEP] 1 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg dai


thalidomide [SEP] 4 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as


myelosuppression [SEP] s progressed during therapy. Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of

Bone Marrow Diseases [SEP]


fatigue [SEP] g therapy. Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern

Fatigue [SEP] The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and re


somnolence [SEP] . Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occu


depressed mood [SEP]  adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four

Depressive Disorder [SEP] An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood distur


neuropathy [SEP]  included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembol

Nervous System Diseases [SEP] Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, periph


dyspnea [SEP] suppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. O

Dyspnea [SEP] Difficult or labored breathing.


thromboembolic [SEP] , neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response

Thromboembolism [SEP] Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.


lenalidomide [SEP] vel reported with the second generation immunomodulatory agent, lenalidomide.

lenalidomide [SEP]


epinephrine [SEP] Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency d

Epinephrine [SEP] The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes


priapism [SEP] Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.

Priapism [SEP] A prolonged painful erection that may lasts hours and is not associated with sexual activity. It is seen in patients with SICKLE


Priapism [SEP] Priapism is the prolonged erection of the penis in the absence of sexual


cocaine [SEP] ence of sexual arousal. A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separat

Cocaine [SEP] An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinic


priapism [SEP] ncy Department (ED) on two separate occasions with a history of priapism after cocaine use. The management options in the ED, as exempli


epinephrine [SEP] ticular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.


green tea [SEP] Effect of green tea and vitamin E combination in isoproterenol induced myocardial i

Plant Extracts [SEP] Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is ev


vitamin E [SEP] Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in r

Vitamin E [SEP] A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydr


isoproterenol [SEP] Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.

Isoproterenol [SEP] Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. I


myocardial infarction [SEP] of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.

Myocardial Infarction [SEP] NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).


green tea [SEP]  present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzyme


vitamin E [SEP]  was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid perox


isoproterenol [SEP] xidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats. Adult male albino


ISO [SEP] enous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats. Adult male albino rats,


myocardial infarction [SEP] dants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats. Adult male albino rats, treated with ISO (200 mg/kg, s


Ca [SEP] n of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decreas

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


Na [SEP] cant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels. Administration of green tea

Sodium [SEP] A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.


K [SEP] (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels. Administration of green tea (10

Potassium [SEP] An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cat


Mg [SEP] ase in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels. Administration of green tea (100 mg/kg/day, p.

Magnesium [SEP] A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of


ocular myasthenia [SEP] Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic

Myasthenia Gravis [SEP] A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed agai


pegylated interferon [SEP] Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.

peginterferon alfa-2b [SEP]


ribavirin [SEP] evelopment of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.

Ribavirin [SEP] A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.


chronic hepatitis C [SEP] sthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.

Hepatitis C, Chronic [SEP] INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead


diplopia [SEP] A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) a

Diplopia [SEP] A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated


pegylated interferon (IFN) alpha-2b [SEP]  experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic exa

peginterferon alfa-2b [SEP]


ribavirin [SEP] ks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations show


chronic hepatitis C [SEP] ration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right u


CHC [SEP] nterferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper


ptosis on the right upper lid [SEP] r chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurologica

Blepharoptosis [SEP] Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.


restricted right eye movement [SEP] almologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study and

Ocular Motility Disorders [SEP] Disorders that feature impairment of eye movements as a primary manifestation of disease. These conditions may be divided into i


acetylcholine [SEP] repetitive nerve stimulation test indicated no abnormality. The acetylcholine receptor antibody titer and response to acetylcholinesterase in

Acetylcholine [SEP] A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathe


pegylated IFN alpha-2b [SEP] ical symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin. The ocular myasthenia associated with combinatio

peginterferon alfa-2b [SEP]


ocular myasthenia [SEP] er discontinuation of pegylated IFN alpha-2b and ribavirin. The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b a


IFN [SEP] plopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalm

peginterferon alfa-2b [SEP]


glycine [SEP] The glycine transporter-1 inhibitor SSR103800 displays a selective and spec

Glycine [SEP] A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also


Schizophrenia [SEP] Schizophrenia has been initially associated with dysfunction in dopamine neur

Schizophrenia [SEP] A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALL


dopamine [SEP] Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission. However, the observation that antagonists of

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


glutamate [SEP] otransmission. However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like

Glutamic Acid [SEP] A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in th


N-methyl-D-aspartate [SEP] ion. However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans h

N-Methylaspartate [SEP] An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NM


NMDA [SEP] rvation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led


schizophrenic [SEP] s of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning


glycine [SEP] ic system via a modulation of the NMDA receptor. Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indir


hyperactivity [SEP] e properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) o

Hyperkinesis [SEP] Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.


amphetamine [SEP] n models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/

Amphetamine [SEP] A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blockin


MK-801 [SEP] ractivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)). Result

Dizocilpine Maleate [SEP] A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The dr


haloperidol [SEP]  knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsyc

Haloperidol [SEP] A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoa


olanzapine [SEP]  p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in a

olanzapine [SEP]


clozapine [SEP] rtantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these mo

Clozapine [SEP] A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system rec


aripiprazole [SEP] classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperacti

aripiprazole [SEP]


catalepsy [SEP] tivity. However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o. Together these

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


Phenylephrine [SEP] Phenylephrine but not ephedrine reduces frontal lobe oxygenation following an

Phenylephrine [SEP] An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.


ephedrine [SEP] Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced h

Ephedrine [SEP] A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may als


reduces frontal lobe oxygenation [SEP] Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.

Hypoxia, Brain [SEP] A reduction in brain oxygen supply due to ANOXEMIA (a reduced amount of oxygen being carried in the blood by HEMOGLOBIN), or to


hypotension [SEP] e reduces frontal lobe oxygenation following anesthesia-induced hypotension.

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


hypotension [SEP] OUND: Vasopressor agents are used to correct anesthesia-induced hypotension. We describe the effect of phenylephrine and ephedrine on front


phenylephrine [SEP] rrect anesthesia-induced hypotension. We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following


ephedrine [SEP] nduced hypotension. We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-ind


fentanyl [SEP] uced hypotension. METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients rece

Fentanyl [SEP] A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is


propofol [SEP] lowing induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv)

Propofol [SEP] An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very shor


stroke [SEP]  to restore mean arterial pressure (MAP). Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation

Stroke [SEP] A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA o


a decrease in MAP [SEP] re registered. RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2). Afte


obsessive-compulsive-like behaviors [SEP] A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals.

Obsessive-Compulsive Disorder [SEP] An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, though


obsessive-compulsive disorder [SEP] BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation


OCD [SEP] GROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a


anxiety [SEP] mptom provocation or a genetic association with stereotypies or anxiety. None of these current models demonstrate multiple OCD-like beh

Anxiety Disorders [SEP] Persistent and disabling ANXIETY.


antidepressant [SEP] haviors. METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and b

Antidepressive Agents [SEP] Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE


clomipramine [SEP] S: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally t

Clomipramine [SEP] A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily a


Clomipramine [SEP] d 16 twice daily and behaviorally tested in adulthood. RESULTS: Clomipramine exposure in immature rats produced significant behavioral and b


memory impairment [SEP] neous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfu

Memory Disorders [SEP] Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory


hoarding [SEP] earning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were el

Obsessive Hoarding [SEP] Persistent difficulty discarding or parting with possessions, regardless of the value of these possessions. Epidemiological stud


Dopamine [SEP] win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


serotonin [SEP] n. Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbita

Serotonin [SEP] A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily i


psychiatric disorders [SEP] or current and future therapeutic strategies for this and other psychiatric disorders.

Mental Disorders [SEP] Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of tho


hemolytic uremic syndrome [SEP] Late recovery of renal function in a woman with the hemolytic uremic syndrome.

Hemolytic-Uremic Syndrome [SEP] A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by


hemolytic uremic syndrome [SEP] A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives. She was treated wi


HUS [SEP] A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives. She was treated with he


oral contraceptives [SEP] ported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives. She was treated with heparin, dipyridamole and hemodialysis; a

Contraceptives, Oral [SEP] Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are


heparin [SEP] US) in a woman taking oral contraceptives. She was treated with heparin, dipyridamole and hemodialysis; and after more than three month

Heparin [SEP] A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges


dipyridamole [SEP] woman taking oral contraceptives. She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary

Dipyridamole [SEP] A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dip


anuria [SEP] ary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possi

Anuria [SEP] Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urina


oliguria [SEP] ults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adul

Oliguria [SEP] Decreased URINE output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1


hypertension [SEP] urely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with

Hypertension [SEP] Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is c


microangiopathic hemolytic anemia [SEP] bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.

Anemia, Hemolytic [SEP] A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red bl


acetylsalicylic acid [SEP] Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocar

Aspirin [SEP] The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties a


dipyridamole [SEP] Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in


hydrocortisone [SEP] Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.

Hydrocortisone [SEP] The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically,


epinephrine [SEP] ts of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.

Epinephrine [SEP] The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes


myocardial injury [SEP] c acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.

Cardiomyopathies [SEP] A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classifi


myocardial injury [SEP] A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardiopr


epinephrine [SEP] A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effe


myocardial infarction [SEP] of agents or maneuvers which might alter the evolution of acute myocardial infarction. Infusions of epinephrine (4 mug per kilogram per minute for 6

Myocardial Infarction [SEP] NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).


radiocalcium [SEP] inephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular comp

Calcium Radioisotopes [SEP] Unstable isotopes of calcium that decay or disintegrate emitting radiation. Ca atoms with atomic weights 39, 41, 45, 47, 49, and


calcium [SEP] rine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular comp

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


calcium chloride [SEP] .0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight). Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq. per lit

Calcium Chloride [SEP] A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning.


acetylsalicylic acid [SEP] uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epineph


dipyridamole [SEP] ly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2


hydrocortisone [SEP] ls pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 c


Acetylsalicylic acid [SEP] damage was graded as less severe in the three treatment groups. Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprot


depressive [SEP] Changes in depressive status associated with topical beta-blockers.

Depressive Disorder [SEP] An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood distur


Depression [SEP] Depression and sexual dysfunction have been related to side effects of top


sexual dysfunction [SEP] Depression and sexual dysfunction have been related to side effects of topical beta-blockers. We

Sexual Dysfunction, Physiological [SEP] Physiological disturbances in normal sexual performance in either the male or the female.


timolol [SEP]  determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side ef

Timolol [SEP] A beta-adrenergic antagonist similar in action to PROPRANOLOL. The levo-isomer is the more active. Timolol has been proposed as


betaxolol [SEP]  selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects. Eight glaucomatous patients chroni

Betaxolol [SEP] A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.


glaucomatous [SEP] tive beta-blocker (betaxolol) regarding CNS side effects. Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering f

Glaucoma [SEP] An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the int


depression [SEP] ients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the stud


ifosfamide [SEP] Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tu

Ifosfamide [SEP] Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.


renal toxicity [SEP] Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an Intern

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


malignant mesenchymal tumors [SEP]  follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.

Malignant mesenchymal tumor [SEP]


malignant mesenchymal tumors [SEP] The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide

Malignant mesenchymal tumor [SEP]


ifosfamide [SEP] mal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncol


Malignant Mesenchymal Tumor [SEP] motherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completio

Malignant mesenchymal tumor [SEP]


ifosfamide, vincristine, and dactinomycin [SEP] ive doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages

IVA protocol [SEP]


IVA [SEP] (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages range

IVA protocol [SEP]


cisplatin [SEP] vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patient

Cisplatin [SEP] An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and inter


tumor [SEP] The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamid

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


glucosuria [SEP]  was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine

Glycosuria, Renal [SEP] An autosomal inherited disorder due to defective reabsorption of GLUCOSE by the PROXIMAL RENAL TUBULES. The urinary loss of gluc


proteinuria [SEP] gated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, p

Proteinuria [SEP] The presence of proteins in the urine, an indicator of KIDNEY DISEASES.


aminoaciduria [SEP] uring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubula

Renal Aminoacidurias [SEP] A group of inherited kidney disorders characterized by the abnormally elevated levels of AMINO ACIDS in URINE. Genetic mutations


creatinine [SEP] glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulin

Creatinine [SEP]


phosphate [SEP] a, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria

Phosphates [SEP] Inorganic salts of phosphoric acid.


renal abnormalities [SEP] nts (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities. Two subsets of patients were identified from this latter group


toxicity [SEP]  four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group in

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


Fanconi's syndrome [SEP] the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevat

Fanconi Syndrome [SEP] A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY


TDFS [SEP] ) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated bet


mesenchymal tumors [SEP] The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide

Malignant mesenchymal tumor [SEP]


dopamine [SEP] Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


nicotine [SEP] for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.

Nicotine [SEP] Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimu


hyperactivity [SEP] t of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.

Hyperkinesis [SEP] Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.


nicotine [SEP] drug or to the experimental environment is necessary to observe nicotine-induced locomotor stimulation. In the present study the role of


dopamine [SEP] fect of nicotine in rats was examined. In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation w


Nicotine [SEP] assessed in male Sprague-Dawley rats tested in photocell cages. Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity


increase in locomotor activity [SEP] d in photocell cages. Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had o


mecamylamine [SEP] ion of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indi

Mecamylamine [SEP] A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine h


hexamethonium [SEP] gonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central n

Hexamethonium [SEP] A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gast


hyperactivity [SEP] bably mediated by central nicotinic receptors. Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selec


SCH 23390 [SEP] nduced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonis

SCH 23390 [SEP]


raclopride [SEP]  selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine. Pretreatment with the D2

Raclopride [SEP] A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.


fluphenazine [SEP] the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine. Pretreatment with the D2 agonist PHNO enhanced nicotine-induce

Fluphenazine [SEP] A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.


SKF 38393 [SEP] enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect. The results indicate that acute nicotine injecti

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine [SEP] A selective D1 dopamine receptor agonist used primarily as a research tool.


mefloquine [SEP] Neuropsychiatric side effects after the use of mefloquine.

Mefloquine [SEP] A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few s


mefloquine [SEP]  neuropsychiatric side effects in patients after treatment with mefloquine. Reactions consisted mainly of seizures, acute psychoses, anxie


seizures [SEP]  after treatment with mefloquine. Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of s

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


psychoses [SEP]  with mefloquine. Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.

Psychoses, Substance-Induced [SEP] Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance.


anxiety neurosis [SEP] quine. Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm. Side effects occu

Anxiety Disorders [SEP] Persistent and disabling ANXIETY.


disturbances of sleep-wake rhythm [SEP] ainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm. Side effects occurred after both therapeutic and prophylactic

Sleep Disorders [SEP] Conditions characterized by disturbances of usual sleep patterns or behaviors. Sleep disorders may be divided into three major c


malaria [SEP] gher than after prophylaxis. Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.

Malaria [SEP] A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIU


pain [SEP] Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac c

Pain [SEP] An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.


lidocaine [SEP] Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.

Lidocaine [SEP] A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more pro


pain [SEP] Previous reports have suggested that pain associated with the injection of lidocaine is related to the ac


lidocaine [SEP] ports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution. To determine if th


mazindol [SEP] Randomized, double-blind trial of mazindol in Duchenne dystrophy.

Mazindol [SEP] Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptak


Duchenne dystrophy [SEP] Randomized, double-blind trial of mazindol in Duchenne dystrophy.

Muscular Dystrophy, Duchenne [SEP] An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the int


weakness [SEP] idence that growth hormone may be related to the progression of weakness in Duchenne dystrophy. We conducted a 12-month controlled trial

Muscle Weakness [SEP] A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be character


Duchenne dystrophy [SEP] growth hormone may be related to the progression of weakness in Duchenne dystrophy. We conducted a 12-month controlled trial of mazindol, a putati


mazindol [SEP] Duchenne dystrophy. We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with


Mazindol [SEP] e expected rate of progression of weakness at P less than 0.05. Mazindol did not benefit strength at any point in the study. Side effect


decreased appetite [SEP] nt in the study. Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointe

Eating Disorders [SEP] A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.


dry mouth [SEP] cts attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (

Xerostomia [SEP] Decreased salivary flow.


gastrointestinal symptoms [SEP] d appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients. The effe

Signs and Symptoms, Digestive [SEP] Digestive system manifestations of diseases of the gastrointestinal system or of other organs.


Pentoxifylline [SEP] Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hypere

Pentoxifylline [SEP] A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing ery


Trental [SEP] Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: impl


dipyridamole [SEP] Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thall

Dipyridamole [SEP] A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dip


hyperemia [SEP] ylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.

Hyperemia [SEP] The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. H


thallium [SEP] amole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.

Thallium [SEP] A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.


Dipyridamole [SEP] Dipyridamole-thallium-201 imaging is often performed in patients unable to e


thallium [SEP] Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise b


peripheral vascular disease [SEP] ng is often performed in patients unable to exercise because of peripheral vascular disease. Many of these patients are taking pentoxifylline (Trental), a

Peripheral Vascular Diseases [SEP] Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.


pentoxifylline [SEP]  peripheral vascular disease. Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve interm


Trental [SEP] ular disease. Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent cl


methylxanthine [SEP] . Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication. Whether

methylxanthine [SEP]


intermittent claudication [SEP] ylline (Trental), a methylxanthine derivative which may improve intermittent claudication. Whether pentoxifylline inhibits dipyridamole-induced coronary

Intermittent Claudication [SEP] A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and wea


dipyridamole [SEP] rove intermittent claudication. Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as t


hyperemia [SEP] . Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be s


methylxanthines [SEP] ine inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamol

methylxanthine [SEP]


theophylline [SEP] e-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imagin

Theophylline [SEP] A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous sys


pentoxyifylline [SEP] y lower after theophylline (p less than 0.01). We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even a


death [SEP] Cause of death among patients with Parkinson's disease: a rare mortality due t

Death [SEP] Irreversible cessation of all bodily functions, manifested by absence of spontaneous breathing and total loss of cardiovascular


Parkinson's disease [SEP] Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.

Parkinson Disease [SEP] A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency


cerebral haemorrhage [SEP] mong patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.

Cerebral Hemorrhage [SEP] Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with


death [SEP] Causes of death, with special reference to cerebral haemorrhage, among 240 pati


cerebral haemorrhage [SEP] Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's di


Parkinson's disease [SEP] al haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy


pneumonia [SEP] es in Japan from 1981 to 1985. The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart dise

Pneumonia [SEP] Inflammation of any part, segment or lobe, of the lung parenchyma.


bronchitis [SEP] om 1981 to 1985. The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), ce

Bronchitis [SEP] Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCH


neoplasms [SEP] auses of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


heart diseases [SEP]  pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cere

Heart Diseases [SEP] Pathological conditions involving the HEART including its structural and functional abnormalities.


cerebral infarction [SEP] is (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11t

Cerebral Infarction [SEP] The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of th


septicaemia [SEP]  (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause o

Sepsis [SEP] Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dys


Cerebral haemorrhage [SEP] ases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only


deaths [SEP]  11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of


hypotensive [SEP] e of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced n

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


levodopa [SEP]  with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels

Levodopa [SEP] The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can b


noradrenaline [SEP] e effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.

Norepinephrine [SEP] Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Nor


parkinsonian [SEP] ypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.


ribavirin [SEP] Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.

Ribavirin [SEP] A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.


Argentine hemorrhagic fever [SEP] Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.

Hemorrhagic Fever, American [SEP] Diseases caused by American hemorrhagic fever viruses (ARENAVIRUSES, NEW WORLD).


ribavirin [SEP] Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF


Argentine hemorrhagic fever [SEP] nd antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution. Administration of ribav


AHF [SEP] rin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution. Administration of ribavirin


viremia [SEP] on. Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers. The average time of

Viremia [SEP] The presence of viruses in the blood.


death [SEP] and a drop of endogenous interferon titers. The average time of death was delayed. A reversible anemia was the only adverse effect ob


anemia [SEP] ron titers. The average time of death was delayed. A reversible anemia was the only adverse effect observed. From these results, we co

Anemia [SEP] A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.


Dipyridamole [SEP] Dipyridamole-induced myocardial ischemia.

Dipyridamole [SEP] A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dip


myocardial ischemia [SEP] Dipyridamole-induced myocardial ischemia.

Myocardial Ischemia [SEP] A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may


Angina [SEP] Angina and ischemic electrocardiographic changes occurred after admini

Angina Pectoris [SEP] The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is


dipyridamole [SEP] ctrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization p


myocardial ischemia [SEP] reoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coron


coronary artery disease [SEP] hemia has been demonstrated to occur in animals and humans with coronary artery disease. Epicardial coronary collateral vessels were demonstrated in al

Coronary Artery Disease [SEP] Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerot


ischemia [SEP]  dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coron

Ischemia [SEP] A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS,


Nitroprusside [SEP] Nitroprusside-induced hypotension evokes ACTH secretion which is primarily me

Nitroprusside [SEP] A powerful vasodilator used in emergencies to lower blood pressure or to improve cardiac function. It is also an indicator for f


hypotension [SEP] Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced s


arginine vasopressin [SEP] ial-portal circulation. Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm. Applic

Arginine Vasopressin [SEP] The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfid


oxytocin [SEP] ortal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm. Application of a de

Oxytocin [SEP] A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino a


corticosterone [SEP] ion of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blo

Corticosterone [SEP] An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman


urethane [SEP] ignal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocortico

Urethane [SEP] Antineoplastic agent that is also used as a veterinary anesthetic. It has also been used as an intermediate in organic synthesis


nitroprusside [SEP] 40 micrograms/dl. Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticos


catalepsy [SEP] Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.

Catalepsy [SEP] A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. Th


delta 9-tetrahydrocannabinol [SEP] Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.

Dronabinol [SEP] A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabino


delta 9-tetrahydrocannabinol [SEP] of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHD


THC [SEP] m in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or


6-hydroxydopamine [SEP] a 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locu

Oxidopamine [SEP] A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in th


6-OHDA [SEP] binol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coerul


desipramine [SEP]  effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated

Desipramine [SEP] A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine


haloperidol [SEP] ith control rats. On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and

Haloperidol [SEP] A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoa


catalepsy [SEP] renergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in c


alfentanil [SEP] Intracranial pressure increases during alfentanil-induced rigidity.

Alfentanil [SEP] A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recov


rigidity [SEP] Intracranial pressure increases during alfentanil-induced rigidity.

Muscle Rigidity [SEP] Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected m


alfentanil [SEP] Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats. Ten rats had arterial, central venous


rigidity [SEP] racranial pressure (ICP) was measured during alfentanil-induced rigidity in rats. Ten rats had arterial, central venous (CVP), and subdu


halothane [SEP] ial, central venous (CVP), and subdural cannulae inserted under halothane anesthesia. The animals were mechanically ventilated to achieve

Halothane [SEP] A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analg


somatic rigidity [SEP] ence from halothane anesthesia. In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP


metocurine [SEP] variables returned to baseline when rigidity was abolished with metocurine. In five rats that did not become rigid, ICP and CVP did not ch

metocurine [SEP]


cis-platin [SEP] se cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.

Cisplatin [SEP] An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and inter


5-fluorouracil [SEP] cts during induction chemotherapy treatment with cis-platin and 5-fluorouracil.

Fluorouracil [SEP] A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTH


head and neck carcinoma [SEP] Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surge

Head and Neck Neoplasms [SEP] Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus.


esophageal carcinoma [SEP] Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery. Obviously, there is a

Esophageal Neoplasms [SEP] Tumors or cancer of the ESOPHAGUS.


cis-platin [SEP] ere is a need for effective chemotherapy. In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous


5-FU [SEP] therapy. In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) we


cardiovascular disease [SEP] dings were performed. In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%). During treatment, adverse card

Cardiovascular Diseases [SEP] Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.


cardiotoxicity [SEP] as the same as for the entire group, 64 years. The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


chest pain [SEP] atment evaluation. The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation. This was followed b

Chest Pain [SEP] Pressure, burning, or numbness in the chest.


atrial fibrillation [SEP]  signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation. This was followed by ventricular fibrillation in one patient a

Atrial Fibrillation [SEP] Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the


ventricular fibrillation [SEP] ST-T wave changes and atrial fibrillation. This was followed by ventricular fibrillation in one patient and sudden death in another. It is concluded tha

Ventricular Fibrillation [SEP] A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (40


sudden death [SEP] his was followed by ventricular fibrillation in one patient and sudden death in another. It is concluded that patients on 5-FU treatment sho

Death, Sudden [SEP] The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiov


tachyarrhythmia [SEP]  and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.

Tachycardia [SEP] Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturba


Verapamil [SEP] Verapamil-induced carbamazepine neurotoxicity. A report of two cases.

Verapamil [SEP] A calcium channel blocker that is a class IV anti-arrhythmia agent.


carbamazepine [SEP] Verapamil-induced carbamazepine neurotoxicity. A report of two cases.

Carbamazepine [SEP] An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but s


neurotoxicity [SEP] Verapamil-induced carbamazepine neurotoxicity. A report of two cases.

Neurotoxicity Syndromes [SEP] Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method


carbamazepine [SEP] Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed co


neurotoxicity [SEP] Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recover


verapamil [SEP] ns of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium e


calcium [SEP] verapamil showed complete recovery after discontinuation of the calcium entry blocker. Use of verapamil in combination with carbamazepi

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


auditory neurotoxicity [SEP] Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.

Hearing Disorders [SEP] Conditions that impair the transmission of auditory impulses and information from the level of the ear to the temporal cortices,


deferoxamine [SEP] Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.

Deferoxamine [SEP] Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in th


auditory neurotoxicity [SEP] Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion


anemia [SEP] usly documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneo

Anemia [SEP] A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.


iron [SEP] 9 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine. Twenty-

Iron [SEP] A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBI


deferoxamine [SEP] o were receiving iron chelation therapy with daily subcutaneous deferoxamine. Twenty-two patients in the affected group had abnormal audiogr


abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz [SEP] ous deferoxamine. Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels. When

Hearing Loss, High-Frequency [SEP] Hearing loss in frequencies above 1000 hertz.


permanent disability [SEP] ned abnormal and four patients required hearing aids because of permanent disability. Since 18 of the 22 patients were initially receiving deferoxam

Deafness [SEP] A general term for the complete loss of the ability to hear from both ears.


auditory abnormality [SEP] s, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was de


toxicity [SEP] Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


ototoxicity [SEP] use-and-effect relation between deferoxamine administration and ototoxicity. Based on these data, a plan of management was developed that a


hearing loss [SEP] /kg per dose with careful monitoring. In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiog

Hearing Loss [SEP] A general term for the complete or partial loss of the ability to hear from one or both ears.


auditory dysfunction [SEP] ng patients with normal serum ferritin values and in those with auditory dysfunction.


Flurbiprofen [SEP] Flurbiprofen in the treatment of juvenile rheumatoid arthritis.

Flurbiprofen [SEP] An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in


juvenile rheumatoid arthritis [SEP] Flurbiprofen in the treatment of juvenile rheumatoid arthritis.

Arthritis, Juvenile [SEP] Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic


juvenile rheumatoid arthritis [SEP] Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/k


flurbiprofen [SEP] ients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant


arthritis [SEP] Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/k

Arthritis [SEP]


swelling [SEP] ments were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morni

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


gastrointestinal (GI) bleeding [SEP] lood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients. One patient was prematurely discontinued fro

Gastrointestinal Hemorrhage [SEP] Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.


headache [SEP]  patient was prematurely discontinued from the study for severe headache and abdominal pain. Most side effects were mild and related to

Headache [SEP] The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACH


abdominal pain [SEP] prematurely discontinued from the study for severe headache and abdominal pain. Most side effects were mild and related to the GI tract.

Abdominal Pain [SEP] Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue inju


neurotoxic [SEP] The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in r


mipafox [SEP] The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.

mipafox [SEP]


neuropathic damage [SEP] tion between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.

Nervous System Diseases [SEP] Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, periph


neuropathic damage [SEP] The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzy


neurotoxic [SEP] The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats

Neurotoxicity Syndromes [SEP] Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method


neuropathy [SEP] een neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mip


Mipafox [SEP] thy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic org

mipafox [SEP]


N, N'-diisopropylphosphorodiamidofluoridate [SEP] t enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate. Brain and spinal cord NTE activ

mipafox [SEP]


organophosphate [SEP] fox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate. Brain and spinal cord NTE activities were measured in Long-Eva

Organophosphates [SEP] Carbon-containing phosphoric acid derivatives. Included under this heading are compounds that have CARBON atoms bound to one or


cord damage [SEP]  These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days

Spinal Cord Diseases [SEP] Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimening


Cerebral infarction [SEP] Cerebral infarction with a single oral dose of phenylpropanolamine.

Cerebral Infarction [SEP] The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of th


phenylpropanolamine [SEP] Cerebral infarction with a single oral dose of phenylpropanolamine.

Phenylpropanolamine [SEP] A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic


Phenylpropanolamine [SEP] Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar


PPA [SEP] Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to a


amphetamine [SEP] A), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants

Amphetamine [SEP] A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blockin


seizures [SEP] arations. Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhe

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


intracerebral hemorrhage [SEP] Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarct

Cerebral Hemorrhage [SEP] Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with


neuropsychiatric symptoms [SEP] se has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction. We report the case of

Mental Disorders [SEP] Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of tho


cerebral infarction [SEP] ebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction. We report the case of a young woman who suffered a cerebral in


psoriasis [SEP] Treatment of psoriasis with azathioprine.

Psoriasis [SEP] A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.


azathioprine [SEP] Treatment of psoriasis with azathioprine.

Azathioprine [SEP] An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthr


Azathioprine [SEP] Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from


psoriasis [SEP] ent benefited 19 (66%) out of 29 patients suffering from severe psoriasis. Haematological complications were not troublesome and results


cholestasis [SEP] ts of biochemical liver function tests remained normal. Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degre

Cholestasis [SEP] Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EX


fibrosis [SEP] ed normal. Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight. Liver biopsies should be under

Fibrosis [SEP] Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other


azathioprine [SEP] ht. Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be det


liver damage [SEP] tervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


lithium [SEP] Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional

Lithium [SEP] An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of


Ebstein's anomaly [SEP] Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.

Ebstein Anomaly [SEP] A congenital heart defect characterized by downward or apical displacement of the TRICUSPID VALVE, usually with the septal and p


lithium [SEP] graphy was used to evaluate two neonates whose mothers ingested lithium during pregnancy. In one infant, Ebstein's anomaly of the tricu


Ebstein's anomaly [SEP] whose mothers ingested lithium during pregnancy. In one infant, Ebstein's anomaly of the tricuspid valve was identified. In the other infant cros


cardiac malformations [SEP] vasive assessment of the presence or absence of lithium-induced cardiac malformations.

Heart Diseases [SEP] Pathological conditions involving the HEART including its structural and functional abnormalities.


myocardial infarction [SEP] Effects of training on the extent of experimental myocardial infarction in aging rats.

Myocardial Infarction [SEP] NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).


isoproterenol [SEP] The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rat

Isoproterenol [SEP] Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. I


myocardial infarction [SEP] he effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of


infarcts [SEP] pecific duration and for a particular period. The occurrence of infarcts were confirmed by histological methods. Elevations in the serum

Infarction [SEP] Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most


isoproterenols [SEP] evations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls. These changes in the seru


polyethylene glycol 400 [SEP] Effect of polyethylene glycol 400 on adriamycin toxicity in mice.

Polyethylene Glycols [SEP] Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular


adriamycin [SEP] Effect of polyethylene glycol 400 on adriamycin toxicity in mice.

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


toxicity [SEP] Effect of polyethylene glycol 400 on adriamycin toxicity in mice.

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


polyethylene glycol 400 [SEP] The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment


PEG 400 [SEP] fect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adr


adriamycin [SEP] 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice. PEG 400 impressively decreased bot


ADR [SEP]  toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice. PEG 400 impressively decreased both acu


cardiac morphological alterations [SEP] ic analysis showed a significant protection against ADR-induced cardiac morphological alterations. Such treatment did not diminish the ADR antitumor activity in

Cardiomyopathies [SEP] A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classifi


L1210 leukemia [SEP] . Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.

Leukemia L1210 [SEP]


Ehrlich ascites tumor [SEP] ot diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.

Carcinoma, Ehrlich Tumor [SEP] A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse.


BCNU [SEP] Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central

Carmustine [SEP] A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other ma


malignant gliomas [SEP] Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.

Glioma [SEP] Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymo


BCNU [SEP] Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial adminis


1,3-bis-(2-chloroethyl)-1-nitrosourea [SEP] Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial ad


malignant gliomas [SEP]  advantage over intravenous administration for the treatment of malignant gliomas. Thirty-six patients were treated with BCNU every 6 to 8 weeks,


astrocytomas [SEP] mg/sq m body surface area. Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior

Astrocytoma [SEP] Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic


tumor [SEP]  or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy. After two to seven cycles of c

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


edema [SEP] , nine patients showed a decrease in tumor size and surrounding edema on contrast-enhanced computerized tomography scans. In the nine

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


loss of vision [SEP] NU. A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis. The frequency of visual loss

Vision Disorders [SEP] Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peri


retinal vasculitis [SEP] nine patients has been unilateral loss of vision secondary to a retinal vasculitis. The frequency of visual loss decreased after the concentration

Retinal Vasculitis [SEP] Inflammation of the retinal vasculature with various causes including infectious disease; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPL


visual loss [SEP] s of vision secondary to a retinal vasculitis. The frequency of visual loss decreased after the concentration of the ethanol diluent was lo


ethanol [SEP] equency of visual loss decreased after the concentration of the ethanol diluent was lowered.

Ethanol [SEP] A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bacterici


noradrenaline [SEP] Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats.

Norepinephrine [SEP] Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Nor


Sodium chloride [SEP] Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micro

Sodium Chloride [SEP] A ubiquitous sodium salt that is commonly used to season food.


noradrenaline [SEP] Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for fi


hypertension [SEP] one kidney removed. Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously. Intrar

Hypertension [SEP] Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is c


cimetidine [SEP] Age and renal clearance of cimetidine.

Cimetidine [SEP] A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacol


cimetidine [SEP] In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the i


creatinine [SEP] is of cimetidine by high-pressure liquid chromatography and for creatinine. Cimetidine clearance decreased with age. The extrapolated 6-hr

Creatinine [SEP]


Cimetidine [SEP] dine by high-pressure liquid chromatography and for creatinine. Cimetidine clearance decreased with age. The extrapolated 6-hr serum conce


dementia [SEP] f cimetidine is a saturable process. There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/

Dementia [SEP] An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occup


kidney disease [SEP] l 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml. Thus, high c

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


clear cell adenocarcinoma [SEP] Development of clear cell adenocarcinoma in DES-exposed offspring under observation.

Adenocarcinoma, Clear Cell [SEP] An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three


DES [SEP] Development of clear cell adenocarcinoma in DES-exposed offspring under observation.

Diethylstilbestrol [SEP] A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as


clear cell adenocarcinoma [SEP] Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in u


adenocarcinoma of the vagina [SEP] Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethy

Vaginal Neoplasms [SEP] Tumors or cancer of the VAGINA.


diethylstilbestrol [SEP] vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported. One patient, aged 23, had been followed for 2 yea


carcinoma [SEP] Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in u

Carcinoma [SEP] A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It i


Phenobarbitone [SEP] Phenobarbitone-induced enlargement of the liver in the rat: its relationship t

Phenobarbital [SEP] A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC AC


enlargement of the liver [SEP] Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced ci

Hepatomegaly [SEP] Enlargement of the liver.


carbon tetrachloride [SEP] nduced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.

Carbon Tetrachloride [SEP] A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic


cirrhosis [SEP] er in the rat: its relationship to carbon tetrachloride-induced cirrhosis.

Fibrosis [SEP] Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other


cirrhosis of the liver [SEP] The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular h

Liver Cirrhosis [SEP] Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably


ascites [SEP] as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenome

Ascites [SEP] Accumulation or retention of free fluid within the peritoneal cavity.


splenomegaly [SEP]  ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half nor

Splenomegaly [SEP] Enlargement of the spleen.


atrophy [SEP] ss than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetr

Atrophy [SEP] Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as


carbon tetrachloride [SEP] lar atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was inc


phenobarbitone [SEP]  12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial


enlargement of the liver [SEP]  carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver. At this point it was assumed that the cytochrome P450/CCl4 tox


CCl4 [SEP] he liver. At this point it was assumed that the cytochrome P450/CCl4 toxic state was both maximal and stable. The optimal rat size t


lithium [SEP] Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.

Lithium [SEP] An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of


diabetes-insipidus-like syndrome [SEP] Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.

Diabetes Insipidus [SEP] A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiolog


amiloride [SEP] tion of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.

Amiloride [SEP] A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a


amiloride [SEP] The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium c


lithium [SEP] The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentratio


polydipsia [SEP] The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, br

Polydipsia [SEP] Excessive thirst manifested by excessive fluid intake. It is characteristic of many diseases such as DIABETES MELLITUS; DIABETES


polyuria [SEP] The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney,

Polyuria [SEP] Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABET


LiCl [SEP]  blood cells was investigated in rats, chronically treated with LiCl. Amiloride reduced the drinking and urine volume of rats in an

Lithium Chloride [SEP] A salt of lithium that has been used experimentally as an immunomodulator.


Amiloride [SEP]  cells was investigated in rats, chronically treated with LiCl. Amiloride reduced the drinking and urine volume of rats in an acute (6 or


diabetes-insipidus-like syndrome [SEP]  In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio betwee


potassium [SEP] ulla and its levels in the blood and an elevation in the plasma potassium level. It is concluded that acute amiloride administration to l

Potassium [SEP] An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cat


alprazolam [SEP] Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.

Alprazolam [SEP] A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC


agoraphobia [SEP] Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.

Agoraphobia [SEP] Obsessive, persistent, intense fear of open places.


panic disorder [SEP] ide-effects of alprazolam. Controlled study in agoraphobia with panic disorder.

Panic Disorder [SEP] A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin wi


benzodiazepines [SEP] BACKGROUND: The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects. Th

Benzodiazepines [SEP] A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring.


alprazolam [SEP] creasing recognition of their unwanted effects. The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-ef


panic disorder [SEP] eir unwanted effects. The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profil


agoraphobia [SEP] . The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug g


depression [SEP] azolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects,

Depressive Disorder [SEP] An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood distur


enuresis [SEP] nts developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particula

Enuresis [SEP] Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytim


aggression [SEP] eactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, im

Mental Disorders [SEP] Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of tho


irritability [SEP] n and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia. Side-effects tended t


impaired memory [SEP] on; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia. Side-effects tended to diminish during

Memory Disorders [SEP] Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory


weight loss [SEP] -effects, particularly sedation, irritability, impaired memory, weight loss and ataxia. Side-effects tended to diminish during treatment bu

Weight Loss [SEP] Decrease in existing BODY WEIGHT.


ataxia [SEP] ularly sedation, irritability, impaired memory, weight loss and ataxia. Side-effects tended to diminish during treatment but remained

Ataxia [SEP] Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes,


Alprazolam [SEP] t week 8. Despite this, the drop-out rate was low. CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but ma


Dup 753 [SEP] Dup 753 prevents the development of puromycin aminonucleoside-induced n

Losartan [SEP] An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.


puromycin aminonucleoside [SEP] Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.

Puromycin Aminonucleoside [SEP] PUROMYCIN derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. It is an antibiotic with antineopl


nephrosis [SEP] 3 prevents the development of puromycin aminonucleoside-induced nephrosis.

Nephrosis [SEP] Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secon


nephrotic syndromes [SEP] The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and

Nephrotic Syndrome [SEP] A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in


proteinuria [SEP] The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood ni

Proteinuria [SEP] The presence of proteins in the urine, an indicator of KIDNEY DISEASES.


hypoalbuminemia [SEP] The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, indu

Hypoalbuminemia [SEP] A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased h


hypercholesterolemia [SEP] ce of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injecti

Hypercholesterolemia [SEP] A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th per


blood nitrogen urea [SEP] teinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was

Blood Urea Nitrogen [SEP] The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% highe


puromycin aminonucleoside [SEP] ncrease in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losar


Dup 753 [SEP] minonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a do


losartan [SEP] oside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or


angiotensin II [SEP] inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The res

Angiotensin II [SEP] An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino aci